Menumenu
  • Home
  • Drug safety study Publications

Drug safety study Publications

Drug safety study Publications

  • Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands.Abstract

    OBJECTIVE: Coumarin anticoagulants are prone to potentially life-threatening drug-drug interactions due to a combination of unfavorable properties. However, real life data on the actual occurrence are scarce. The aim of this study was to quantify ad qualify potential drug interactions with coumarin anticoagulants in daily practice

    Penning-van Beest FJ, Koerselman J, Herings RM. Pharm World Sci. 2007 Dec; 29 (6): 671-5.
  • Early Evidence on the Effects of Regulators’ Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents.Abstract

    OBJECTIVE: In 2003 and 2004, U.S. and European regulators issued public health warnings about a possible association between antidepressants and suicidal thinking and behavior. The authors assessed whether these warnings discouraged use of antideprssants in children and adolescents and whether they led to increases in suicide rates as a result of untreated depression

    Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ. Am J Psychiatry. 2007 Sep; 164 (9): 1356-63.
  • In-hospital use of opioids increases rate of coded postoperative paralytic ileus.Abstract

    PURPOSE: To determine the association between opioid use and the occurrence of postoperative paralytic ileus (POI) after different types of surgery. METHODS: The PHARMO database was used to perform a case control study in which intramural drug utilsation data were linked to hospital discharge diagnoses

    Goettsch WG, Sukel MP, van der Peet DL, van Riemsdijk MM, Herings RM. Pharmacoepidemiol Drug Saf. 2007 Jun; 16 (6): 668-74.
  • Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study.Abstract

    INTRODUCTION: Administration of beta-2 agonists decreased bone mineral density in rats. But the association between bronchodilators and fracture risk has not been studied in humans. OBJECTIVES: To examine the association between use of beta-2 agonits and risk of hip/femur fracture. METHODS: We conducted a population-based case-control study (6763 cases) in the Dutch PHARMO database

    de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP. Pharmacoepidemiol Drug Saf. 2007 Jun; 16 (6): 612-9.
  • Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.Abstract

    OBJECTIVE: To assess whether there is an association between initial use of serotonergic antidepressants and changes in antiparkinsonian drug treatment. METHODS: A retrospective cohort study was performed with the PHARMO record linkage system. Allatients from 1994 until 2004 of 40 years or older who were first time users of an antidepressant and who had used a levodopa-containing drug at least 180 days before initiation of the antidepressant were included

    Arbouw ME, Movig KL, Neef C, Guchelaar HJ, Egberts TC. Eur J Clin Pharmacol. 2007 Feb; 63 (2): 181-7.
  • Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.Abstract

    Patients using higher dosages of inhaled or oral glucocorticoids (GCs) have an increased risk of hip/femur fractures. The role of the underlying disease in the aetiology of this increased risk has not been widely studied. Objective. To evaluate thecontribution of the underlying disease to the risk of hip/femur fracture in patients using inhaled or oral GCs

    de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staa TP. J Intern Med. 2007 Feb; 261 (2): 170-7.
  • Risk of ischemic complications related to the intensity of triptan and ergotamine use.Abstract

    OBJECTIVE: To investigate whether the intensity of triptan and ergotamine use, in specific overuse, is associated with the risk of ischemic complications. METHODS: We conducted a retrospective nested case-control study using data from the PHARMO Reord Linkage System. All patients with more than one prescription for either a triptan or ergotamine were initially identified

    Wammes-van der Heijden EA, Rahimtoola H, Leufkens HG, Tijssen CC, Egberts AC. Neurology. 2006 Oct 10; 67 (7): 1128-34.
  • Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme..Abstract

    Results from clinical trials and clinical practice have shown statins to be generally well tolerated with a low frequency of clinically relevant side effects. Nevertheless, there are rare occasions when adverse events (AEs), sometimes serious, mayccur. Rosuvastatin is the newest statin to be approved in the USA and many other countries

    Johansson S, EE Ming, MA Wallander , LA Rodriquez, Herings RM, Goettsch W, A Gonzales-Perez, AT McAfee, AM Walker. Pharmacoepidemiol Drug Saf. 2006 July; 15 (7): 454-61.
  • Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study..Abstract

    PURPOSE: Clinical benefits of statin therapy are accepted, but their safety profiles have been under scrutiny, particularly for the recently introduced statin, rosuvastatin, relating to serious adverse events involving muscle, kidney and liver. Theefore, a historical cohort study was performed to evaluate the association between rosuvastatin versus other statin use and the incidence of rhabdomyolysis, myopathy, acute renal failure and hepatic impairment

    Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Herings RM. Pharmacoepidemiol Drug Saf. 2006 July; 15 (7): 435-43.
  • Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population.Abstract

    The aim of the present study was to assess whether the use of angiotensin-converting enzyme (ACE) inhibitors is associated with a decreased risk of hospitalisation for community-acquired pneumonia (CAP) in a general, essentially white population. Dta were obtained from the Dutch PHARMO Record Linkage System

    van deGarde EM, Souverein PC, van den Bosch JM, Deneer VH, Leufkens HG. Eur Respir J. 2006 Jun; 27 (6): 1217-22.